细胞周期蛋白E2在下咽癌中的表达及其意义

doi:10.6040/j.issn.1673-3770.0.2020.352

摘要/Abstract

摘要： 目的观察细胞周期蛋白E2在下咽癌组织中的表达水平及其与临床病理特征及预后的相互关系。方法免疫组化法检测50例下咽癌肿瘤组织及相应的正常黏膜组织中细胞周期蛋白E2的表达水平,分析其与临床特征及生存率的相互关系,结果采用SPSS 18.0软件进行统计分析。结果细胞周期蛋白E2在下咽癌组织中的表达较正常黏膜组织明显增加(Z=-5.764,P=0.000),且其表达程度与肿瘤的临床分期(Z=-1.995, P=0.046)、淋巴结转移(Z=-2.176,P=0.030)相关。肿瘤组织中细胞周期蛋白E2表达阳性患者5年生存率为40.2%,阴性表达患者5年生存率为81.8%。细胞周期蛋白E2表达水平高的患者生存率明显降低(χ2=6.317,P=0.012)。结论细胞周期蛋白E2在下咽癌肿瘤组织中的异常表达提示其可能参与了肿瘤的发生发展,并有可能成为下咽癌的诊断、治疗与预后的分子标志物之一。

关键词: 细胞周期蛋白E2, 下咽癌, 数据库检索, 免疫组化, 生存分析, 预后因子

Abstract: Objective This study aims to evaluate the level of expression of cyclin E2 in hypopharyngeal cancer and its relationship with clinical characteristics as well as prognosis. Methods The protein levels of cyclin E2 in tumor tissues and adjacent normal tissues were assessed by immunohistochemistry staining in 50 cases of hypopharyngeal cancer. The relationship between the expression level of cyclin E2 and clinical data was analyzed using the SPSS software. Results Protein levels of cyclin E2 in hypopharyngeal cancer were higher than protein levels of cyclin E2 in normal tissue(Z=-5.764,P=0.000). The cyclin E2 level in tumor tissue correlated with the tumor staging(Z=-1.995, P=0.046)and lymph node metastasis(Z=-2.176, P=0.030). The 5-year survival rates of patients with cyclin E2 positive and negative expression were 40.2% and 81.8%, respectively. Patients with high expression levels of cyclin E2 had a lower survival rate(χ2=6.317, P=0.012). Conclusion The abnormal expression of cyclin E2 protein in tumor tissues indicates that cyclin E2 may be involved in the development of hypopharyngeal cancer and could be a potential diagnostic and prognostic molecular marker.

Key words: Cyclin E2, Hypopharyngeal carcinoma, Database retrieval, Immunohistochemistry, Survival analysis, Prognosis factor

中图分类号:

R739.63

黄俊伟,陈学军,刘宏飞,陶冶,李祖飞,陈平,张洋. 细胞周期蛋白E2在下咽癌中的表达及其意义[J]. 山东大学耳鼻喉眼学报, 2020, 34(5): 132-137.

参考文献

[1] Parfenov M, Pedamallu CS, Gehlenborg N, et al. Characterization of HPV and host genome interactions in primary head and neck cancers[J]. Proc Natl Acad Sci USA, 2014,111:15544-15549. doi: 10.1073/pnas.1416074111.
[2] 黄志刚. CO₂激光手术治疗咽喉部肿瘤[J]. 山东大学耳鼻喉眼学报, 2018, 32(6): 1-3. doi:10.6040/j.issn.1673-3770.1.2018.022. HUANG Zhigang. Treatment of throat tumors with CO₂ laser[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2018, 32(6): 1-3. doi:10.6040/j.issn.1673-3770.1.2018.022.
[3] Chen NX, Liu K, Liu X, et al. Induction and regulation of the immunoproteasome subunit β5i(PSMB8)in laryngeal and hypopharyngeal carcinoma cells[J]. Med Sci Monit, 2020, 26: e923621-1-e923621-11. doi:10.12659/msm.923621.
[4] Stamatakos M, Palla V, Karaiskos I, et al. Cell cyclins: triggering elements of cancer or not?[J]. World J Surg Oncol, 2010, 8: 111. doi:10.1186/1477-7819-8-111.
[5] Perez-Neut M, Shum A, Cuevas BD, et al. Stimulation of hERG1 channel activity promotes a calcium-dependent degradation of cyclin E2, but not cyclin E1, in breast cancer cells[J]. Oncotarget, 2015, 6(3): 1631-1639. doi:10.18632/oncotarget.2829.
[6] Patch AM, Christie EL, Etemadmoghadam D, et al. Whole-genome characterization of chemoresistant ovarian cancer[J]. Nature, 2015, 521(7553): 489-494. doi:10.1038/nature14410.
[7] Nakayama K, Rahman MT, Rahman M, et al. CCNE1 amplification is associated with aggressive potential in endometrioid endometrial carcinomas[J]. Int J Oncol, 2016, 48(2):506-516. doi: 10.3892/ijo.2015.3268.
[8] Liang WW, Guan HY, He XY, et al. Down-regulation of SOSTDC1 promotes thyroid cancer cell proliferation via regulating cyclin A2 and cyclin E2[J]. Oncotarget, 2015, 6(31): 31780-31791. doi:10.18632/oncotarget.5566.
[9] Zhao ZY, Liu JT, Wang CL, et al. MicroRNA-25 regulates small cell lung cancer cell development and cell cycle through cyclin E2[J]. Int J Clin Exp Pathol, 2014, 7(11): 7726-7734.
[10] Chen D, Guo WJ, Qiu ZP, et al. MicroRNA-30d-5p inhibits tumour cell proliferation and motility by directly targeting CCNE2 in non-small cell lung cancer[J]. Cancer Lett, 2015, 362(2): 208-217. doi:10.1016/j.canlet.2015.03.041.
[11] Feng W, Wang C, Liang C, et al. The Dysregulated Expression of KCNQ1OT1 and Its Interaction with Downstream Factors miR-145/CCNE2 in Breast Cancer Cells[J]. Cell Physiol Biochem, 2018, 49(2):432-446. doi: 10.1159/000492978.
[12] Xie L, Li T, Yang LH. E2F2 induces MCM4, CCNE2 and WHSC1 upregulation in ovarian cancer and predicts poor overall survival[J]. Eur Rev Med Pharmacol Sci, 2017, 21(9): 2150-2156.
[13] Tormo E, Adam-Artigues A, Ballester S, et al. The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene[J]. Sci Rep, 2017, 7: 41309. doi:10.1038/srep41309.
[14] Schwaederlé M, Daniels GA, Piccioni DE, et al. Cyclin alterations in diverse cancers: Outcome and co-amplification network[J]. Oncotarget, 2015, 6(5): 3033-3042. doi:10.18632/oncotarget.2848.
[15] Kanska J, Zakhour M, Taylor-Harding B, et al. Cyclin E as a potential therapeutic target in high grade serous ovarian cancer[J]. Gynecol Oncol, 2016, 143(1): 152-158. doi:10.1016/j.ygyno.2016.07.111.
[16] Sheldon LA. Inhibition of E2F1 activity and cell cycle progression by arsenic via retinoblastoma protein[J]. Cell Cycle, 2017, 16(21): 2058-2072. doi:10.1080/15384101.2017.1338221.
[17] Geng Y, Michowski W, Chick JM, et al. Kinase-independent function of E-type cyclins in liver cancer[J]. Proc Natl Acad Sci USA, 2018, 115:1015-1020. doi: 10.1073/pnas.1711477115.
[18] Sun Q, Yu R, Wang CF, et al. Correction to: Circular RNA circ-CSPP1 regulates CCNE2 to facilitate hepatocellular carcinoma cell growth via sponging miR-577[J]. Cancer Cell Int, 2020, 20: 293. doi:10.1186/s12935-020-01339-z.
[19] Zhu C, Huang Q, Zhu H. miR-383 Inhibited the Cell Cycle Progression of Gastric Cancer Cells via Targeting Cyclin E2 [J]. DNA Cell Biol, 2019, 38(8):849-856. doi:10.1089/dna.2019.4624.
[20] Yu AQ, Wang ZX, Wu W, et al. Circular RNA CircCCNB1 sponges micro RNA-449a to inhibit cellular senescence by targeting CCNE2 [J]. Aging(Albany NY), 2019, 11(22):10220-10241. doi:10.18632/aging.102449.
[21] Gao P, Wang H, Yu J, et al. miR-3607-3p suppresses non-small cell lung cancer(NSCLC)by targeting TGFBR1 and CCNE2 [J]. PLoS Genet, 2018, 14(12):e1007790. doi:10.1371/journal.pgen.1007790.
[22] Gorjala P, Cairncross JG, Gary RK. p53-dependent up-regulation of CDKN1A and down-regulation of CCNE2 in response to beryllium [J]. Cell Prolif, 2016, 49(6):698-709. doi:10.1111/cpr.12291.
[23] Xu W, Taranets L, Popov N. Regulating Fbw7 on the road to cancer [J]. Semin Cancer Biol, 2016, 36:62-70. doi:10.1016/j.semcancer.2015.09.005.
[24] Capaldo CT, Koch S, Kwon M, et al. Tight function zonula occludens-3 regulates cyclin D1-dependent cell proliferation[J]. Mol Biol Cell, 2011, 22(10): 1677-85. doi: 10.1091/mbc.E10-08-0677.
[25] Peek GW, Tollefsbol TO. Combinatorial PX-866 and raloxifene decrease Rb phosphorylation, cyclin E2 transcription, and proliferation of MCF-7 breast cancer cells[J]. J Cell Biochem, 2016, 117(7): 1688-1696. doi:10.1002/jcb.25462.

相关文章 15

[1]	陈东彦,钱晔,魏东敏,李文明,夏同良,雷大鹏,潘新良. 高频超声诊断下咽鳞癌淋巴结转移的临床研究[J]. 山东大学耳鼻喉眼学报, 2022, 36(5): 18-23.
[2]	姜超,周炫辰,韩杰,岳志勇. IVc期下咽癌特征分析及列线图预后模型构建[J]. 山东大学耳鼻喉眼学报, 2022, 36(4): 49-54.
[3]	程瑶,张震,杨吉,冯成敏,邓启成,张西,赵锐,朱鑫,吴俊志,刘海,邓世山. CIP2A在下咽癌中的表达及临床意义[J]. 山东大学耳鼻喉眼学报, 2022, 36(2): 40-44.
[4]	冯成敏,敬一丹,刘海,王冰. 咽喉部鳞状细胞癌细胞系[J]. 山东大学耳鼻喉眼学报, 2021, 35(6): 113-124.
[5]	王中卫,杨林,郭亚,孙斌,王亚利,马秀龙,任宏涛,包兴. 鼻咽癌患者miR-429、miR-200C表达与预后关系分析[J]. 山东大学耳鼻喉眼学报, 2021, 35(3): 81-86.
[6]	王亚越,孙娟. 下咽癌中差异表达的蛋白激酶及抑制剂的研究进展[J]. 山东大学耳鼻喉眼学报, 2021, 35(1): 119-124.
[7]	崔小缓,李丽娜,张延平,蒋兴旺,毕欣欣,冉桃桃,吴莹莹,刘雅莉. 改良负压封闭引流装置在难治性咽瘘治疗中的应用[J]. 山东大学耳鼻喉眼学报, 2020, 34(6): 49-53.
[8]	岳建林,林云,姜震,李学新,孙睿杰,潘新良,刘大昱. 半侧舌根组织瓣在咽腔侧方缺损修复中的应用[J]. 山东大学耳鼻喉眼学报, 2020, 34(1): 63-66.
[9]	崔晓波. 诱导化疗在局部晚期下咽癌治疗中的意义[J]. 山东大学耳鼻喉眼学报, 2019, 33(4): 10-17.
[10]	黄泽雷,宋琦,路秀英,崔兰珍,李晓明. 双氢青蒿素对下咽癌Fadu细胞内质网应激途径的作用[J]. 山东大学耳鼻喉眼学报, 2019, 33(4): 31-35.
[11]	黄河,欧阳晖. 下咽癌共病食管癌的高危因素及预后分析[J]. 山东大学耳鼻喉眼学报, 2019, 33(4): 82-86.
[12]	黄志刚. CO₂激光手术治疗咽喉部肿瘤[J]. 山东大学耳鼻喉眼学报, 2018, 32(6): 1-3.
[13]	张孟璐,李永团. 继发性胆脂瘤中CCL27的定位及检测[J]. 山东大学耳鼻喉眼学报, 2017, 31(6): 46-48.
[14]	李晓明,宋琦,李红霞,陶振峰,申宇鹏,肖淑芬. 胸大肌肌皮瓣在侵犯下咽晚期头颈鳞癌手术切除术后缺损修复中的应用[J]. 山东大学耳鼻喉眼学报, 2016, 30(3): 4-9.
[15]	董频,英信江,陈歆维,邓志宏,张少强,於子卫,金斌,孙臻峰,谢晋,祝江才. 新辅助化疗方案尼妥珠单抗联合奈达铂和5-氟尿嘧啶治疗下咽鳞癌初步临床分析[J]. 山东大学耳鼻喉眼学报, 2016, 30(3): 10-14.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed